Alector, Inc. Profile Avatar - Palmy Investing

Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment…

Biotechnology
US, South San Francisco [HQ]

Risk Factors

By Management
Not Available

    No Risk Factor available yet. You can request "Risk Factors" through an email.

End of ALEC's Analysis
CIK: 1653087 CUSIP: 014442107 ISIN: US0144421072 LEI: - UEI: -
Secondary Listings
ALEC has no secondary listings inside our databases.